Case report: Gaucher disease in trepanobiopsy of 16yo woman examined for suspected myelodysplastic syndrome

Czech version

Authors: Vladimír Židlík ^1,4; Tomáš Kuhn ²; Pavel Hurník ^1,3,4; Mária Wozniaková ^1,4; Barbora Mičulková ^1,3,4; Dušan Žiak ^1,3; Marie Sporková ¹; Patricie Delongová ^1,4; Jaroslav Horáček ¹; Jiří Ehrmann ¹
Authors‘ workplace: Ústav patologie, Fakultní nemocnice Ostrava, Ostrava ¹; Klinika dětského lékařství, Fakultní nemocnice Ostrava, Ostrava ²; CGB laboratoř a. s., Ostrava ³; Lékařská fakulta, Ostravská univerzita, Ostrava ⁴
Published in: Čes.-slov. Patol., 57, 2021, No. 2, p. 105-108
Category: Original Articles

Overview

Gaucher disease is an autosomal recessive disease belonging to the so-called storage diseases. More than 300 mutations of the GBA1 gene encoding the β-glucocerebrosidase enzyme are known. It is a very rare disease in the Czech Republic. Currently 35 patients are treated. In our case report, we present the case of a 16 year old female patient attending the Clinic of Pediatric Medicine at the University Hospital in Ostrava. Since 2007, the patient has suffered prolonged thrombocytopenia, at the time with progression, and splenomegaly, which has not been further investigated. Trepanobiopsy was sent to the Department of Pathology with suspicion of myelodysplastic syndrome in May of 2018. In the biopsy examination, the individual bloodline did not show dysplastic features and the number of blasts was not increased. The marrow interstitium was 70% permeated with gaucher cells with intraplasmatic fibrous material. Cells were in the appearance of „crumpled paper“ and expressed CD68 in immunohistochemical stain and in histochemical examination of PAS and iron (Fe) staining. Based on a morphological finding, Gaucher‘s disease was suspected. Repeated bone marrow aspirates were subsequently captured by gaucher cells, and a next biochemical examination showed a β-glucocerebrosidase enzyme decrease of activity. Gaucher disease is a progressive disease that requires early diagnosis with the onset of therapy.

Keywords:

Gaucher disease – gaucher cells – storage diseases – β-glucocerebrosidase

Sources

1. Linari S, Castaman G. Clinical manifestations and management of Gaucher disease. Clin Cases Miner Bone Metab 2015; 12(2): 157-164.

2. Cappellini MD. A rare condition in haematological practise – Gaucher disease. European Oncology & Haematology 2015; 11(1): 15–20.

3. Malinová V, Mazurová S, Dvořáková L. Gaucherova choroba a lysozomální onemocnění – současné možnosti diagnostiky a léčby. Remedia, ročník 26, číslo 3/2016.

4. Rosenbloom EB, Weinreb JN. Gaucher Disease: a comprehensive review. Crit Rev Oncog 2013; 18(3): 163-175.

5. Stirnemann J, Belmatoug N, Camou F, et al. A review of Gaucher disease pathophysiology, clinical presentation and treatments. Int J Mol Sci 2017; 18(2): 441.

6. Baris NH, Cohen JI, Mistry KP. Gaucher Disease: the metabolic defect, pathophysiology, Phenotypes and natural history. Pediatr Endocrinol Rev 2014; 12(01): 72-81.

7. Huang WJ, Zhang X, Chen WW. Gaucher disease: a lysosomal neurodegenerative disorder. Eur Rev Med Pharmacol Sci 2015; 19(7): 1219-1226.

8. Hruska SK, LaMarca EM, Scott RC, Sindransky E. Gaucher Disease: mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). Hum Mutat 2008; 29(5): 567-583.

9. Bohra V, Nair V. Gaucher’s disease. Indian J Endocrinol Metab 2011; 15(3): 182-186.

10. Jmoudiak M, Futerman AH. Gaucher disease: pathological mechanisms and modern management. Br J Haematol 2005; 129(2): 178-188.